CanSino Biologics Inc Total Liabilities

Latest as of December 2025: €2.22 Billion EUR ≈ $2.60 Billion USD

CanSino Biologics Inc total liabilities. Based on the latest financial reports, CanSino Biologics Inc (CJH) has total liabilities worth €2.22 Billion EUR (≈ $2.60 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CanSino Biologics Inc (CJH) asset resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of CanSino Biologics Inc (2016–2025)

Total liabilities of CanSino Biologics Inc from 2016 to 2025. This chart illustrates how CanSino Biologics Inc's total liabilities have evolved over time, based on quarterly financial data.

CanSino Biologics Inc Competitors by Total Liabilities

The table below lists competitors of CanSino Biologics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Hinova Pharmaceuticals Inc. A SHG:688302	China	CN¥255.12 Million
Jereissati Participações S.A. SA:IGTI3	Brazil	R$5.13 Billion
Everbright Jiabao Co Ltd SHG:600622	China	CN¥16.59 Billion
Viromed Medical AG DU:Q11	Germany	€69.84 Million
Hua Eng Wire & Cable Co Ltd TW:1608	Taiwan	NT$5.58 Billion
Ausgold Ltd AU:AUC	Australia	AU$23.51 Million
Korea New Network Co. Ltd KQ:058400	Korea	₩13.88 Billion
KKR Credit Income Fund AU:KKC	Australia	AU$27.15 Million

Liability Composition Analysis (2016–2025)

This chart breaks down CanSino Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CanSino Biologics Inc assets under control.

Liquidity & Leverage Metrics

CanSino Biologics Inc Total Liabilities Ratios Explained

CanSino Biologics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	3.55	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.45	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.31	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CanSino Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CanSino Biologics Inc (2016–2025)

The table below shows the annual total liabilities of CanSino Biologics Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€2.22 Billion ≈ $2.60 Billion	-27.04%
2024-12-31	€3.05 Billion ≈ $3.56 Billion	-24.39%
2023-12-31	€4.03 Billion ≈ $4.71 Billion	-4.55%
2022-12-31	€4.22 Billion ≈ $4.94 Billion	+26.97%
2021-12-31	€3.33 Billion ≈ $3.89 Billion	+391.17%
2020-12-31	€677.22 Million ≈ $791.74 Million	+115.69%
2019-12-31	€313.98 Million ≈ $367.08 Million	+6.96%
2018-12-31	€293.56 Million ≈ $343.20 Million	+13.33%
2017-12-31	€259.03 Million ≈ $302.84 Million	+131.90%
2016-12-31	€111.70 Million ≈ $130.59 Million	--

About CanSino Biologics Inc

F:CJH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$449.81 Million

€384.75 Million EUR

Market Cap Rank

#12494 Global

#1356 in Germany

Share Price

€2.90

Change (1 day)

+0.00%

52-Week Range

€2.28 - €5.05

All Time High

€45.99